Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 183
Label UNT Conférences

le (16m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?Speaker: Jim JANUZZI, Boston, USADiscussant: James SNIDER, Critical Diagnostics, USAAbstract : How should Diagnostic and Prognostic Markers BeStudied? The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach with which these potentially important tests have ...
Voir la vidéo
Conférences

le (15m3s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)

MODIGLIANI Workshop 2 - Friday November 30, 2012 :ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALSFacilitating the discovery of effective therapiesChairpersons: Jagat NARULA, New York, USA - Ahmed TAWAKOL, Boston, USAWebcast: Bart STAELS, Lille, FRAPhase III clinical endpoint trials evaluating treatments for atherosclerosis typically require very large sample sizes, cost hundreds of millions of dollars and historically have had very low success rates. As a result, few new therapies that attenuate the progression of atherosclerosis have been identified in over 30 years (since the discovery of statins). Nearly a decade ago, in recognition of the low success of Phase III trials, regulatory agencies ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte